Skip to content
10-K

Annual Report

KalVista Pharmaceuticals, Inc. KALV

0000950170-25-095011

← back to feed
Filed
Jul 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jun 25, 2025 49.95M sh
Shares Diluted FY 2025 · Apr 30, 2025 49.65M sh
Shares Diluted FY 2025 · Apr 30, 2024 36.79M sh
Capex FY 2025 · Apr 30, 2025 $434K
Capex FY 2025 · Apr 30, 2024 $42K
Operating Cash Flow FY 2025 · Apr 30, 2025 −$152.91M
Operating Cash Flow FY 2025 · Apr 30, 2024 −$89.23M
Cash And Equivalents FY 2025 · Apr 30, 2025 $131.62M
Cash And Equivalents FY 2025 · Apr 30, 2024 $31.79M
Stockholders Equity FY 2025 · Apr 30, 2025 $95.39M
Stockholders Equity FY 2025 · Apr 30, 2024 $206.58M
Stockholders Equity FY 2025 · Apr 30, 2023 $161.03M
Current Liabilities FY 2025 · Apr 30, 2025 $45.17M
Current Liabilities FY 2025 · Apr 30, 2024 $22.81M
Current Assets FY 2025 · Apr 30, 2025 $241.69M
Current Assets FY 2025 · Apr 30, 2024 $225.69M
Total Assets FY 2025 · Apr 30, 2025 $250.77M
Total Assets FY 2025 · Apr 30, 2024 $235.4M
Eps Diluted FY 2025 · Apr 30, 2025 −$3.69
Eps Diluted FY 2025 · Apr 30, 2024 −$3.44
Eps Basic FY 2025 · Apr 30, 2025 −$3.69
Eps Basic FY 2025 · Apr 30, 2024 −$3.44
Rd Expense FY 2025 · Apr 30, 2025 $71.71M
Rd Expense FY 2025 · Apr 30, 2024 $86.17M
Net Income restated FY 2025 · Apr 30, 2025 −$183.44M
Net Income restated FY 2025 · Apr 30, 2024 −$126.64M
Operating Income FY 2025 · Apr 30, 2025 −$188M
Operating Income FY 2025 · Apr 30, 2024 −$140.45M